Bausch Health Companies (NYSE:BHC) Upgraded by StockNews.com to “Buy”

StockNews.com upgraded shares of Bausch Health Companies (NYSE:BHCFree Report) from a hold rating to a buy rating in a research report sent to investors on Wednesday.

Bausch Health Companies Stock Down 0.1 %

Bausch Health Companies stock opened at $8.13 on Wednesday. The company has a quick ratio of 0.89, a current ratio of 1.20 and a debt-to-equity ratio of 74.20. Bausch Health Companies has a 12-month low of $5.57 and a 12-month high of $10.23. The firm’s fifty day moving average is $7.83 and its 200 day moving average is $7.91. The company has a market capitalization of $2.93 billion, a PE ratio of -3.08 and a beta of 0.79.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Aviva PLC raised its holdings in Bausch Health Companies by 2.2% during the first quarter. Aviva PLC now owns 45,626 shares of the company’s stock worth $1,044,000 after buying an additional 971 shares during the last quarter. Parallel Advisors LLC grew its stake in shares of Bausch Health Companies by 57.4% in the 2nd quarter. Parallel Advisors LLC now owns 3,262 shares of the company’s stock worth $26,000 after acquiring an additional 1,189 shares in the last quarter. CIBC Asset Management Inc grew its stake in shares of Bausch Health Companies by 0.5% in the 2nd quarter. CIBC Asset Management Inc now owns 267,868 shares of the company’s stock worth $2,145,000 after acquiring an additional 1,428 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Bausch Health Companies by 0.5% in the 3rd quarter. Legal & General Group Plc now owns 296,379 shares of the company’s stock worth $2,455,000 after acquiring an additional 1,565 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Bausch Health Companies by 0.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 211,993 shares of the company’s stock worth $1,696,000 after acquiring an additional 1,945 shares in the last quarter. Institutional investors and hedge funds own 74.56% of the company’s stock.

Bausch Health Companies Company Profile

(Get Free Report)

Bausch Health Companies Inc operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.

Recommended Stories

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.